Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function

Daniel D. Joyce, Christopher J.D. Wallis, Amy N. Luckenbaugh, Heather L. Huelster, Zhiguo Zhao, Karen E. Hoffman, Li Ching Huang, Tatsuki Koyama, Ralph Conwill, Michael Goodman, Ann S. Hamilton, Xiao Cheng Wu, Lisa E. Paddock, Antoinette Stroup, Matthew R. Cooperberg, Mia Hashibe, Brock B.O’ Neil, Sherrie H. Kaplan, Sheldon Greenfield, David F. PensonDaniel A. Barocas

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Sexual dysfunction, including erectile dysfunction and loss of libido, are common among men undergoing treatment for localized prostate cancer. Both local treatments and systemic androgen deprivation therapy may contribute to these outcomes and are differentially indicated based on disease characteristics. We sought to compare sexual function through 5 years after radiation treatment with and without androgen deprivation therapy in men with good baseline sexual function to better understand long-term effects in this understudied subset of patients. Methods: We retrospectively reviewed a prospectively assembled population-based cohort of men who underwent radiation with and without androgen deprivation therapy for intermediate or high-risk localized prostate cancer. Sexual function was assessed longitudinally over 5 years. Men with erections sufficient for intercourse at baseline were selected for inclusion. Results: Out of 167 patients included, 73 underwent radiation alone and 94 received androgen deprivation therapy plus radiation (51 with intermediate and 43 with high-risk disease). Androgen deprivation therapy use was associated with worse sexual function through 1 year regardless of disease risk. This difference was no longer statistically significant at 3 years in the intermediate-risk group. Compared to radiation alone, androgen deprivation therapy in high-risk disease was associated with worse sexual function at 3 years (effect: −20.3 points, CI [−31.8, −8.8], p < 0.001) but not at 5 years (effect: −3.4, CI [−17.2, 10.5], p = 0.63). Conclusions: Androgen deprivation therapy plus radiation is associated with worse sexual function through 3-years follow-up in men with high-risk prostate cancer compared to radiation alone. The addition of androgen deprivation therapy in the treatment of intermediate-risk disease does not appear to result in worse sexual function at 3 or 5-year follow-up compared to radiation alone.

Original languageEnglish (US)
Pages (from-to)238-247
Number of pages10
JournalProstate Cancer and Prostatic Diseases
Volume25
Issue number2
DOIs
StatePublished - Feb 2022
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function'. Together they form a unique fingerprint.

Cite this